JP2021501581A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501581A5
JP2021501581A5 JP2020524267A JP2020524267A JP2021501581A5 JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5 JP 2020524267 A JP2020524267 A JP 2020524267A JP 2020524267 A JP2020524267 A JP 2020524267A JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
polypeptide
gene locus
sequence encoding
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501581A (ja
JP7397791B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058230 external-priority patent/WO2019089610A1/en
Publication of JP2021501581A publication Critical patent/JP2021501581A/ja
Publication of JP2021501581A5 publication Critical patent/JP2021501581A5/ja
Priority to JP2023150855A priority Critical patent/JP2024009805A/ja
Application granted granted Critical
Publication of JP7397791B2 publication Critical patent/JP7397791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524267A 2017-10-30 2018-10-30 初代細胞の遺伝子編集 Active JP7397791B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023150855A JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762579114P 2017-10-30 2017-10-30
US201762579113P 2017-10-30 2017-10-30
US62/579,114 2017-10-30
US62/579,113 2017-10-30
PCT/US2018/058230 WO2019089610A1 (en) 2017-10-30 2018-10-30 Primary cell gene editing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023150855A Division JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Publications (3)

Publication Number Publication Date
JP2021501581A JP2021501581A (ja) 2021-01-21
JP2021501581A5 true JP2021501581A5 (https=) 2021-12-09
JP7397791B2 JP7397791B2 (ja) 2023-12-13

Family

ID=66332290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524267A Active JP7397791B2 (ja) 2017-10-30 2018-10-30 初代細胞の遺伝子編集
JP2023150855A Pending JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023150855A Pending JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Country Status (13)

Country Link
US (7) US10584357B2 (https=)
EP (1) EP3703712A4 (https=)
JP (2) JP7397791B2 (https=)
CN (2) CN117904055A (https=)
AU (1) AU2018357861B2 (https=)
BR (1) BR112020008704A2 (https=)
CA (1) CA3081320A1 (https=)
IL (1) IL274351B2 (https=)
MX (1) MX2020004541A (https=)
RU (1) RU2020116585A (https=)
SG (1) SG11202004026QA (https=)
TW (1) TWI716758B (https=)
WO (1) WO2019089610A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190161530A1 (en) * 2016-04-07 2019-05-30 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性t細胞受容体の標的置換
SG11202004026QA (en) * 2017-10-30 2020-05-28 Pact Pharma Inc Primary cell gene editing
IL277722B2 (en) 2018-04-02 2025-12-01 Pact Pharma Inc Peptide-mhc compacts
CN113227374A (zh) * 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
SG11202111865UA (en) 2019-05-01 2021-11-29 Pact Pharma Inc Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
US20220242929A1 (en) * 2019-08-05 2022-08-04 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making
EP3999651B1 (en) 2019-08-26 2026-03-18 Adoc Ssf, Llc Methods of performing guide-seq on primary human t cells
IL291935A (en) * 2019-10-08 2022-06-01 Pact Pharma Inc Methods for immunotherapy of genetically modified autologous t cells
EP4041293A1 (en) * 2019-10-10 2022-08-17 PACT Pharma, Inc. Method of treating immunotherapy non-responders with an autologous cell therapy
EP4110356A4 (en) * 2020-02-28 2024-03-27 Wisconsin Alumni Research Foundation NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING
WO2021216993A1 (en) * 2020-04-24 2021-10-28 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
CA3181117A1 (en) * 2020-06-12 2021-12-16 Ines MENDE Compositions and methods of manufacturing autologous t cell therapies
MX2023002455A (es) * 2020-08-28 2023-05-16 Arsenal Biosciences Inc Células inmunitarias modificadas con receptores cebadores.
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
JP2024512608A (ja) * 2021-03-24 2024-03-19 ジェネンテック, インコーポレイテッド Tリンパ球における効率的なtcr遺伝子編集
WO2022242644A1 (zh) * 2021-05-18 2022-11-24 赛斯尔擎生物技术(上海)有限公司 修饰细胞的方法
EP4352508A1 (en) 2021-06-11 2024-04-17 Adoc Ssf, Llc Method of assessing cell products
AU2024228388A1 (en) 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
WO2016071343A1 (en) * 2014-11-03 2016-05-12 Immures S.R.L. T cell receptors
EP3359660B1 (en) * 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
JP6816133B2 (ja) * 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ,インク. 改変ヒトt細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
JP2019509738A (ja) 2016-03-11 2019-04-11 ブルーバード バイオ, インコーポレイテッド ゲノム編集された免疫エフェクター細胞
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性t細胞受容体の標的置換
SG11202004026QA (en) * 2017-10-30 2020-05-28 Pact Pharma Inc Primary cell gene editing

Similar Documents

Publication Publication Date Title
JP2021501581A5 (https=)
CN105683215B (zh) 高稳定性的t细胞受体及其制法和应用
IL274200B1 (en) Methods, compositions, and implantable elements comprising active cells
ES2848478T3 (es) Receptores quiméricos para antígenos y usos de estos
JP2022531231A5 (https=)
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2018138049A5 (https=)
RU2020116585A (ru) Редактирование гена первичных клеток
JP2017538401A5 (https=)
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
UA120917C2 (uk) Химерний білок фактора viii та його застосування
JP2017018125A5 (https=)
JP2017537622A5 (https=)
JP2014500724A5 (https=)
WO2021198706A3 (en) Coronavirus vaccines
WO2012159006A8 (en) Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof
JP2020501550A5 (https=)
JP2014508510A5 (https=)
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
JP2018502600A5 (https=)
JP2017513502A5 (https=)
WO2017190684A1 (zh) 白细胞介素组合及其用途
US11932679B2 (en) Agent for restoring visual function or agent for preventing deterioration in visual function
RU2014135053A (ru) Иммуногены для вакцинации против вич